ESI-MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-02. Numbers and descriptions here follow the published literature rather than marketing material.
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
| Property | Value | Notes |
|---|---|---|
| 纯度检测 | RP-HPLC，214 nm | 乙腈/水梯度，含 0.1% 三氟乙酸 |
| 身份确认 | ESI-MS 或 LC-MS/MS | 比对实测与理论分子量 |
| 冻干粉储存 | -20 °C，干燥避光 | 分装可减少开盖次数 |
| 复溶液储存 | 2-8 °C，短期使用 | 避免反复冻融与长时间室温放置 |
| 主要降解途径 | 水解、氧化、脱酰胺 | 碱性 pH 与强光会加快反应 |
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
== History == 2C-B was first synthesized and evaluated by American chemist Alexander Shulgin in 1974. He described the properties and effects of 2C-B in humans, along with those of 2C-D, in the scientific literature in 1975. Shulgin proposed 2C-B and 2C-D for use in psychedelic-assisted psychotherapy. However, it was reportedly abandoned for such purposes due to gastrointestinal side effects and lack of entactogenic effects. 2C-B was Shulgin's favorite psychedelic of his own creations, though he has said that he only tried it a few times.
In May 2023, the FDA approved the iLet Bionic Pancreas system for people with Type 1 diabetes of six years and older. The device uses a closed-loop system to deliver both insulin and glucagon in response to sensed blood glucose levels. The 4th generation iLet prototype, presented in 2017, is around the size of an iPhone, with a touchscreen interface. It contains two chambers for both insulin and glucagon, and the device is configurable for use with only one hormone, or both. A 440-patient study of type I diabetes ran in 2020 and 2021 using a device configuration that delivered only insulin in comparison to standard of care; device use led to better circulating glucose control (measured by continuous monitoring) and a reduction in glycated hemoglobin (versus no change for the standard of care group). However, the incidence of severe hypoglycemic events was more than 1.5 times higher among device users versus standard care patients. There are several non-commercial, non-FDA approved DIY options, using open source code, including OpenAPS, Loop, and/or AndroidAPS.
=== Audio === Todd played the title character in Bleak December Inc.'s 2016 audio drama adaptation of Bram Stoker's Dracula. Todd was the narrator of the spoken word version of Ice Nine Kills' album The Silver Scream, released on June 29, 2023.
1978 Genentech produces biosynthetic human insulin in Escherichia coli bacteria using recombinant DNA techniques, licenses to Eli Lilly 1981 Novo Nordisk chemically and enzymatically converts porcine to human insulin 1982 Genentech synthetic human insulin (above) approved 1983 Eli Lilly and Company produces biosynthetic human insulin with recombinant DNA technology, Humulin 1985 Axel Ullrich sequences a human cell membrane insulin receptor. 1988 Novo Nordisk produces recombinant biosynthetic human insulin 1996 Lilly Humalog "lispro" insulin analogue approved. 2000 Sanofi Aventis Lantus insulin "glargine" analogue approved for clinical use in the US and the EU. 2004 Sanofi Aventis Apidra insulin "glulisine" insulin analogue approved for clinical use in the US. 2006 Novo Nordisk Levemir "detemir" insulin analogue approved for clinical use in the US. 2008 Abbott laboratories " FreeStyle Navigator CGM" gets approved. 2013 The US Food and Drug Administration (FDA) requested more cardiac safety tests for Insulin degludec. 2015 Insulin degludec was approved by the FDA in September 2015.
WSJ added Grist was still "scathing" about both pre-war and wartime actions taken by Georgia, but said that some of his remarks had been misinterpreted and quoted Grist saying, "I have never said there was no provocation by the South Ossetians." In an interview with The Wall Street Journal, Ryan Grist said that on 12 August he went to visit a friend in Tskhinvali, Lira Tskhovrebova. Tskhovrebova had connections with separatist authorities and Grist's meeting with two high-ranking South Ossetian officials was arranged by Grist's Ossetian friends. On the road back to Tbilisi, South Ossetian militia stopped Grist, who called the names of the South Ossetian officials "so they wouldn't shoot" him. It is noteworthy that during 6 August meeting between British ambassador to Georgia Denis Keefe and the South Ossetian leader Eduard Kokoity, Kokoity blasted the OSCE meanwhile praising OSCE's British officer Ryan Grist. In December 2008, an inquiry by the Associated Press found out that Lira Tskhovrebova was not an independent advocate. She was allegedly connected to South Ossetian KGB and Russian intelligence agency, the FSB. Matthew Bryza, Deputy Assistant Secretary of State of the United States, also expressed his doubts about Tskhovrebova.
Sources: en.wikipedia.org
=== Early History (1819-1823) === Physician Daniel Drake founded the Medical College of Ohio, the precursor to the University of Cincinnati College of Medicine, in 1819. It was the first medical school west of the Allegheny Mountains. Originally located in a room above a drugstore, the college graduated its first class of 24 students in 1821.
== Structure == Some brands may have a pellet (spheroid) formulations (made by extrusion and spheronization) can be used for controlled release of the drug in the body whereas powder filled pellets generally cannot. The plastic spheres containing powder have micropores that open at varying pH levels, to maintain a mostly constant release during transit through the digestive tract. The spheres themselves, the outer shells, pass undigested in most patients. Other brands are thought to use ethylcellulose coatings to control drug release from pellets. Another use these medications have is that they can be given via NG tube, the pellets being very small. This makes them one of the few extended release oral medications that can be given by feeding tube.
Willis Carrier moved his facilities from New Jersey to Syracuse, New York, in the 1930s. During the late 20th century, when it was acquired by UTC, it was Central New York State's largest manufacturer. Due to increasing labor and union costs in the Central New York area, Carrier has substantially downsized its presence in Syracuse, with manufacturing work being moved to a variety of domestic and international locations. Meanwhile, managerial employees were moved closer to UTC's corporate headquarters in Farmington, Connecticut, which represented a challenge to the local economy in Syracuse. Over the course of 2011, the majority of the manufacturing buildings of the Syracuse campus were demolished at a cost of nearly $14 million. Despite the loss of manufacturing jobs, the suburban Syracuse Campus, in DeWitt, New York, remained the primary engineering and design center for Carrier products, with over 1,000 employees and contractors on site. This site also houses the Customer Care Call Center for Carrier branded products. In 1980, Carrier was allowed to name the Carrier Dome, the football and basketball arena at Syracuse University, after Mel Holm, the company's then-CEO chair of the university's board of trustees, gave the university $2.75 million toward the facility's construction. Despite being named for an air conditioner manufacturer, the Carrier Dome was not air-conditioned for the first four decades of its lifespan, only having it installed during renovations that were completed in 2022.
The EMC of wood varies with the ambient relative humidity (a function of temperature) significantly, to a lesser degree with the temperature. Siau (1984) reported that the EMC also varies very slightly with species, mechanical stress, drying history of wood, density, extractives content and the direction of sorption in which the moisture change takes place (i.e. adsorption or desorption).
Sources: en.wikipedia.org
肽键在 214 nm 附近有较强吸收，适合检测缺少芳香侧链的短肽。该波长的基线受流动相组成与梯度影响较大。因此流动相与梯度条件需要固定并完整记录。
仅凭保留时间不足以定性，通常需要质谱给出与理论值一致的分子量。进一步可用碎裂谱与参考谱比对。保留时间、分子量与碎裂谱三者吻合时，身份判断较为可靠。
这取决于缓冲液、pH、温度与微生物负荷，并不存在通用时限。常见做法是分装冷冻并尽量缩短室温放置时间。出现浑浊或沉淀时应弃用并重新配制。
碱性 pH、较高温度、强光照射与反复冻融都会加快水解、氧化或脱酰胺。溶液中的金属离子也可能催化氧化。控制这些变量比单纯降低浓度更有效。